Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Dunlop

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
The Journal of Biological Chemistry|February 19, 2017
Deficits in the activity of presynaptic γ-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndromeJi-Yong Kang, Jayashree Chadchankar, Thuy N Vien, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2015
KCC2 activity is critical in limiting the onset and severity of status epilepticusLiliya Silayeva, Tarek Z Deeb, Rochelle M Hines, et al.
Public Health Genomics|May 31, 2016
Gene-Tailored Treatments for Brain Disorders: Challenges and OpportunitiesGiovanni Esposito, Jean Marc Burgunder, John Dunlop, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 19, 2009
Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disordersRenza Roncarati, Carla Scali, Thomas A Comery, et al.
Psychopharmacology|February 14, 2007
Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodentsSharon Rosenzweig-Lipson, Annmarie Sabb, Gary Stack, et al.
BMJ Open|February 7, 2025
Trial protocol of an open-label pilot study of oral <u>na</u>ltrexone-<u>bu</u>propion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial)Krista J Siefried, Liam Acheson, Brendan Clifford, et al.
BMJ Open|July 26, 2022
Iterative delivery of an implementation support package to increase and sustain the routine provision of antenatal care addressing alcohol consumption during pregnancy: study protocol for a stepped-wedge cluster trialEmma Doherty, John Wiggers, Nicole Nathan, et al.
Journal of Medicinal Chemistry|April 4, 2012
Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789)Riccardo Zanaletti, Laura Bettinetti, Cristiana Castaldo, et al.
Bioorganic & Medicinal Chemistry|June 12, 2009
SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonistSimon N Haydar, Chiara Ghiron, Laura Bettinetti, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 4, 2008
Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide)John Dunlop, Tim Lock, Brian Jow, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
The Journal of Biological Chemistry|February 19, 2017
Deficits in the activity of presynaptic γ-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndromeJi-Yong Kang, Jayashree Chadchankar, Thuy N Vien, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2015
KCC2 activity is critical in limiting the onset and severity of status epilepticusLiliya Silayeva, Tarek Z Deeb, Rochelle M Hines, et al.
Public Health Genomics|May 31, 2016
Gene-Tailored Treatments for Brain Disorders: Challenges and OpportunitiesGiovanni Esposito, Jean Marc Burgunder, John Dunlop, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 19, 2009
Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disordersRenza Roncarati, Carla Scali, Thomas A Comery, et al.
Psychopharmacology|February 14, 2007
Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodentsSharon Rosenzweig-Lipson, Annmarie Sabb, Gary Stack, et al.
BMJ Open|February 7, 2025
Trial protocol of an open-label pilot study of oral <u>na</u>ltrexone-<u>bu</u>propion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial)Krista J Siefried, Liam Acheson, Brendan Clifford, et al.
BMJ Open|July 26, 2022
Iterative delivery of an implementation support package to increase and sustain the routine provision of antenatal care addressing alcohol consumption during pregnancy: study protocol for a stepped-wedge cluster trialEmma Doherty, John Wiggers, Nicole Nathan, et al.
Journal of Medicinal Chemistry|April 4, 2012
Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789)Riccardo Zanaletti, Laura Bettinetti, Cristiana Castaldo, et al.
Bioorganic & Medicinal Chemistry|June 12, 2009
SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonistSimon N Haydar, Chiara Ghiron, Laura Bettinetti, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 4, 2008
Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide)John Dunlop, Tim Lock, Brian Jow, et al.
Pageof 10